N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

Study of Out of Specification for Tisagenlecleucel

Sponsor: Novartis Pharmaceuticals • ClinicalTrials.gov ID: NCT04094311

Registry updated: 2026-09-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.

Interventions

  • CTL019 (Biological)
    A single intravenous (i.v.) infusion of CAR-positive viable T cells.

Eligibility criteria

Key inclusion criteria: * Signed informed consent/assent must be obtained for this study prior to participation in the study. * Patients for whom the final manufactured tisagenlecleucel product does not meet the commercial release specifications. * Not excluded from commercial manufacturing under the Health Authority-approved tisagenlecleucel prescribing information for their respective country/region. * OOS material has not been deemed to pose an undue safety risk to the patient. * Patient is suffering from a serious or life-threatening disease or condition. * Repeat leukapheresis is not clinically appropriate per the investigator assessment. Key exclusion criteria: For part 1, patients meeting any of the following criteria are not eligible for inclusion in this study: * Human immunodeficience virus (HIV) positive patients. * Patients with active replication of Hepatitis B virus (HBV) or Hepatitis C virus (HCV). * Patients with primary central nervous system (CNS) lymphoma. * History of hypersensitivity to any drugs or metabolites of similar chemical classes as tisagenlecleucel. * Uncontrolled active infection or inflammation. * Any medical condition identified by the investigator that may impact the assessment of the safety or efficacy outcomes in relation to study treatment. * Pregnant or nursing (lactating) women. For part 2, exclusion criteria are not set; however, administration should be performed in accordance with the latest versions of the package insert of CTL019.

Conditions

B-cell Acute Lymphoblastic Leukemia Diffuse Large B-cell Lymphoma

Locations

  • Novartis Investigative Site — Hamilton, Ontario, Canada
  • Novartis Investigative Site — Ottawa, Ontario, Canada
  • Novartis Investigative Site — Toronto, Ontario, Canada
  • Novartis Investigative Site — Toronto, Ontario, Canada
  • Novartis Investigative Site — Montreal, Quebec, Canada
  • Novartis Investigative Site — Québec, Quebec, Canada
  • Novartis Investigative Site — Nagoya, Aichi-ken, Japan
  • Novartis Investigative Site — Nagoya, Aichi-ken, Japan
  • Novartis Investigative Site — Tōon, Ehime, Japan
  • Novartis Investigative Site — Gifu, Gifu, Japan
  • Novartis Investigative Site — Sapporo, Hokkaido, Japan
  • Novartis Investigative Site — Sapporo, Hokkaido, Japan
  • Novartis Investigative Site — Kobe, Hyōgo, Japan
  • Novartis Investigative Site — Nishinomiya, Hyōgo, Japan
  • Novartis Investigative Site — Tsukuba, Ibaraki, Japan
  • Novartis Investigative Site — Kita-gun, Kagawa-ken, Japan
  • Novartis Investigative Site — Yokohama, Kanagawa, Japan
  • Novartis Investigative Site — Kumamoto, Kumamoto, Japan
  • Novartis Investigative Site — Kyoto, Kyoto, Japan
  • Novartis Investigative Site — Tsu, Mie-ken, Japan
  • Novartis Investigative Site — Sendai, Miyagi, Japan
  • Novartis Investigative Site — Matsumoto, Nagano, Japan
  • Novartis Investigative Site — Nagasaki, Nagasaki, Japan
  • Novartis Investigative Site — Yufu, Oita Prefecture, Japan
  • Novartis Investigative Site — Kurashiki, Okayama-ken, Japan
  • Novartis Investigative Site — Izumi, Osaka, Japan
  • Novartis Investigative Site — Izumisano, Osaka, Japan
  • Novartis Investigative Site — Osaka, Osaka, Japan
  • Novartis Investigative Site — Sakai, Osaka, Japan
  • Novartis Investigative Site — Suita, Osaka, Japan
  • Novartis Investigative Site — Izumo, Shimane, Japan
  • Novartis Investigative Site — Hamamatsu, Shizuoka, Japan
  • Novartis Investigative Site — Bunkyo Ku, Tokyo, Japan
  • Novartis Investigative Site — Bunkyo Ku, Tokyo, Japan
  • Novartis Investigative Site — Bunkyo Ku, Tokyo, Japan
  • Novartis Investigative Site — Bunkyo-ku, Tokyo, Japan
  • Novartis Investigative Site — Bunkyo-ku, Tokyo, Japan
  • Novartis Investigative Site — Chuo Ku, Tokyo, Japan
  • Novartis Investigative Site — Fuchū, Tokyo, Japan
  • Novartis Investigative Site — Fuchū, Tokyo, Japan
  • Novartis Investigative Site — Minato-ku, Tokyo, Japan
  • Novartis Investigative Site — Setagaya-ku, Tokyo, Japan
  • Novartis Investigative Site — Shinjuku-ku, Tokyo, Japan
  • Novartis Investigative Site — Aomori, Japan
  • Novartis Investigative Site — Chiba, Japan
  • Novartis Investigative Site — Fukuoka, Japan
  • Novartis Investigative Site — Hiroshima, Japan
  • Novartis Investigative Site — Ishikawa, Japan
  • Novartis Investigative Site — Kyoto, Japan
  • Novartis Investigative Site — Niigata, Japan
  • Novartis Investigative Site — Okayama, Japan
  • Novartis Investigative Site — Osaka, Japan
  • Novartis Investigative Site — Osaka, Japan
  • Novartis Investigative Site — Saitama, Japan
  • Novartis Investigative Site — Wakayama, Japan
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record